The North Carolina not-for-profit healthcare system selected Omnicell's XT automated cabinets as it seeks to enhance patient-care on nursing floors and in perioperative settings. With our ...

Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results , with sales up 18.6% year on year to $306.9 ...

Healthcare tech company Omnicell (NASDAQ:OMCL) will be reporting results tomorrow morning. Here’s what to expect. Omnicell beat analysts’ revenue expectations by 0.6% last quarter, reporting ...

For the current quarter ending in March, Omnicell expects its per-share earnings to range from 15 cents to 25 cents. The company said it expects revenue in the range of $255 million to $265 million ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Omnicell (OMCL – Research Report). The company’s shares ...

In the latest quarter, 4 analysts provided ratings for Omnicell (NASDAQ:OMCL), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

Get prepared with the key expectations. Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article. Zacks Medical Info Systems industry stocks like Enovis, Omnicell and ...

Omnicell aims to solve this problem. Its products, which consist of automated dispensing systems, medication cabinets and pharmacy robotics, ensure the right medication gets to the right person in ...

(NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter ...

Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...

Analyst Allen Lutz of Bank of America Securities maintained a Hold rating on Omnicell (OMCL – Research Report), retaining the price target of $46.00. Allen Lutz has given his Hold rating due to ...